| Histone H3K27ac separates active from poised enhancers and predicts developmental state MP Creyghton, AW Cheng, GG Welstead, T Kooistra, BW Carey, ... Proceedings of the National Academy of Sciences 107 (50), 21931-21936, 2010 | 5091 | 2010 |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016 | 4145 | 2016 |
| Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... Genome medicine 9 (1), 34, 2017 | 3585 | 2017 |
| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ... Nature biotechnology 31 (11), 1023-1031, 2013 | 2461 | 2013 |
| Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ... Molecular cancer therapeutics 16 (11), 2598-2608, 2017 | 2449 | 2017 |
| Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells A Marson, SS Levine, MF Cole, GM Frampton, T Brambrink, S Johnstone, ... cell 134 (3), 521-533, 2008 | 1820 | 2008 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1641 | 2018 |
| Densely interconnected transcriptional circuits control cell states in human hematopoiesis N Novershtern, A Subramanian, LN Lawton, RH Mak, WN Haining, ... Cell 144 (2), 296-309, 2011 | 1149 | 2011 |
| Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies D Lipson, M Capelletti, R Yelensky, G Otto, A Parker, M Jarosz, JA Curran, ... Nature medicine 18 (3), 382-384, 2012 | 1128 | 2012 |
| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 1004 | 2015 |
| Foxp3 occupancy and regulation of key target genes during T-cell stimulation A Marson, K Kretschmer, GM Frampton, ES Jacobsen, JK Polansky, ... Nature 445 (7130), 931-935, 2007 | 1000 | 2007 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015 | 876 | 2015 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 791 | 2014 |
| Enhancer decommissioning by LSD1 during embryonic stem cell differentiation WA Whyte, S Bilodeau, DA Orlando, HA Hoke, GM Frampton, CT Foster, ... Nature 482 (7384), 221-225, 2012 | 695 | 2012 |
| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 654 | 2020 |
| Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity H Beltran, R Yelensky, GM Frampton, K Park, SR Downing, ... European urology 63 (5), 920-926, 2013 | 596 | 2013 |
| Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells MG Guenther, GM Frampton, F Soldner, D Hockemeyer, M Mitalipova, ... Cell stem cell 7 (2), 249-257, 2010 | 596 | 2010 |
| PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers M Yarchoan, LA Albacker, AC Hopkins, M Montesion, K Murugesan, ... JCI insight 4 (6), e126908, 2019 | 584 | 2019 |
| Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database G Singal, PG Miller, V Agarwala, G Li, G Kaushik, D Backenroth, A Gossai, ... Jama 321 (14), 1391-1399, 2019 | 548 | 2019 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016 | 520 | 2016 |
Alexa SchrockVerified email at foundationmedicine.com
